# Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)

Study · id `cardio:ct-nct07735130` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07735130](<https://clinicaltrials.gov/study/NCT07735130>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07735130

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 632 participants.

## Technical summary

Registry record NCT07735130. Randomized; no masking; primary purpose treatment. Start 2026-08-15 (anticipated); primary completion 2030-06-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 632 participants (planned count; ClinicalTrials.gov record NCT07735130, source copy `cardio:ctgov-nct07735130-2026-07-29`, retrieved 2026-10-26)
- Planned start: 2026-08-15 (anticipated) (ClinicalTrials.gov record NCT07735130, source copy `cardio:ctgov-nct07735130-2026-07-29`, retrieved 2026-10-26)
- Primary completion: 2030-06-15 (anticipated) (ClinicalTrials.gov record NCT07735130, source copy `cardio:ctgov-nct07735130-2026-07-29`, retrieved 2026-10-26)
- Completion: 2030-06-15 (anticipated) (ClinicalTrials.gov record NCT07735130, source copy `cardio:ctgov-nct07735130-2026-07-29`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07735130, source copy `cardio:ctgov-nct07735130-2026-07-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07735130-2026-07-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)
- Acronym: ARBITAR
- Condition: Transcatheter Aortic Valve Replacement (TAVR)
- Condition: Left Ventricular Hypertrophy
- Condition: Severe Aortic Stenosis
- Intervention (Drug): Angiotensin Receptor Blocker (ARB)
- Lead sponsor: Seoul National University Hospital
- Lead sponsor class: OTHER
- Collaborator: Samjin Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- Registry lists this organization as the lead sponsor: Seoul National University Hospital (`cardio:org-seoul-national-university-hospital`)
- Registry lists this organization as a collaborator: Samjin Pharmaceutical Co., Ltd. (`cardio:org-samjin-pharmaceutical-co-ltd`)

## Provenance

Content hash: 6e8976327086c2bdcd0a03fef907df3a0f0a1903f7786b2862b46ce258eef1b6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
